Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays
Open accessThe DOI matches its Crossref record; 309 of the 334 references it cites were found in a registry or an index; 163 of the 299 sources its claims cite were checked for support.
Abstract
Inherited retinal dystrophies and optic neuropathies cause chronic disabling loss of visual function. The development of recombinant adeno-associated viral vectors (rAAV) gene therapies in all disease fields have been promising, but the translation to the clinic has been slow. The safety and efficacy profiles of rAAV are linked to the dose of applied vectors. DNA changes in the rAAV gene cassette affect potency, the expression pattern (cell-specificity), and the production yield. Here, we present a library of rAAV vectors and elements that provide a workflow to design novel vectors. We first performed a meta-analysis on recombinant rAAV elements in clinical trials (2007–2020) for ocular gene therapies. We analyzed 33 unique rAAV gene cassettes used in 57 ocular clinical trials. The rAAV gene therapy vectors used six unique capsid variants, 16 different promoters, and six unique polyadenylation sequences. Further, we compiled a list of promoters, enhancers, and other sequences used in current rAAV gene cassettes in preclinical studies. Then, we give an update on pro-viral plasmid backbones used to produce the gene therapy vectors, inverted terminal repeats, production yield, and rAAV safety considerations. Finally, we assess rAAV transgene and bioactivity assays applied to cells or organoids in vitro, explants ex vivo, and clinical studies.
Overview
CoChat Summary
TL;DR
This review/meta-analysis catalogs recombinant AAV vector elements used in ocular gene therapy clinical trials (2007–2020) and preclinical assays, analyzing 33 unique rAAV gene cassettes from 57 trials. It provides a workflow/library of capsids, promoters, enhancers, introns, polyadenylation sequences, production considerations, and transgene/bioactivity assay models for designing ocular rAAV vectors.
Key findings
- The meta-analysis identified 33 unique rAAV gene cassettes used in 57 ocular clinical trials; these used six unique capsid variants, 16 different promoters, and six unique polyadenylation sequences.
- Five different AAV-RPE65 products were tested in 13 clinical trials, leading to the first retinal gene therapy approved by the FDA in December 2017 and EMA in November 2018 (AAV-hRPE65v2; voretigene neparvovec-rzyl, LUXTURNA).
- The review compiles vector elements including capsids, ubiquitous and cell-specific promoters, enhancers, introns, WPRE, polyadenylation sequences, pro-viral plasmid backbones, ITRs, and production platforms; it notes rAAV packaging capacity of about 4.5–4.6 kb excluding ITRs, while scAAV reduces capacity to a maximum of 2.5 kb including ITRs.
- Assay models reviewed include in vitro cell lines, hiPSC-derived RPE, retinal organoids, ex vivo human retina, and in vivo/NHP studies; NHP and human retinal explants matched more closely (correlation r = 0.66–0.67) than mouse/human comparisons (r = 0.24–0.32).
Methods
- Meta-analysis: clinical trial identifiers were collected from reviews on ocular gene therapy, then searched on clinicaltrials.gov using keywords including AAV, gene therapy, retinitis pigmentosa, RP, Leber congenital amaurosis, LCA, AMD, and CHM, with last search date 01 April 2020; the search was limited to ocular gene therapies and cross-checked against news, reviews, Ph.D. theses, patents, SEC filings, company websites, presentations, and conference abstracts.
- The 33 unique rAAV ocular gene therapy products were analyzed for prokaryotic plasmid backbone, ITR AAV serotype, enhancers, promoters, introns, cDNA genes, codon optimization, human or other species-related sequences, post-transcriptional stabilizing sequences, polyadenylation sequences, and rAAV production platform; missing information was indicated as “UntoldR” or “?”.
- The paper also compiles preclinical promoters, enhancers, and other sequences and reviews transgene expression assays and biological activity assays across in vitro, ex vivo, and in vivo models.
Limitations
- The paper states that many papers on rAAV ocular trials do not sufficiently describe the elements on the plasmid used for viral vector production, including bacterial origin and bacterial selection markers, and that poor description and the vast expanse of rAAV vectors make fair comparison of vector elements very challenging.
- The paper states that large-scale comparative rAAV element studies are missing in ophthalmology; it also notes that rAAV integration studies in the retina are underrepresented and that almost no rAAV study specifically investigated rAAV integration events.
- Evident from the text: as a review/meta-analysis, it does not report new primary experimental data, and missing or incomplete source information is marked as “UntoldR” or “?”, indicating reliance on secondary and sometimes incomplete public/company documentation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4 How to assess Inverted Terminal Repeats (ITRs) of rAAV and how they allow concatemerization. (A) Restriction enzyme sites in the AAV serotype 2 ITR in the flop configuration. RBE’/RBE binds Rep68 (RBE, Rep-binding element) and initiates the Rep helicase. The Rep helicase nicks the trs (terminal resolution site). Restriction enzyme recognition site indicated in blue and the actual cut in red. Figure adapted from [238]. (B) ITR structure in the nucleus after second-strand DNA synthesis in dividing cells favoring homologous recombination. Most rAAV-vectors form episomal concatemeric circular double-stranded DNA.](https://figures.cochat.ai/paper-figures/d2cf029bfc5c418988eb657099b1a410/recombinant-adeno-associated-viral-vectors-raav-vector-elements-in-ocular-gene-figure-4.jpg)
![Figure 5 A hypothetical model of the spread of rAAV capsids (serotypes 1, 2, 5 8, and 9) after intravitreal or subretinal injection in disease or non-disease mouse retinas in vivo based on the studies [99,294,304,306,308,309]. RPE, retinal pigment epithelium; OLM, outer limiting membrane, ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; GCL, ganglion cell layer; ILM, Inner Limiting Membrane.](https://figures.cochat.ai/paper-figures/e3f5847ede504cb38d2d032ab640db72/recombinant-adeno-associated-viral-vectors-raav-vector-elements-in-ocular-gene-figure-5.jpg)

Verification
Claims the paper makes
109 Valid · 57 Not valid · 98 Not checked · 102 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Relative tissue-specific expression of two gRNAs for CRISPR/Cas gene editing in myotubes was achieved by linking a muscle-specific MHCK7 promoter (pol II) with gRNA-linked self-cleaving ribozyme sequences derived of Hepatitis delta virus (HDV) and a Hammerhead (HH) sequence [134-137].”
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 3.5. Small Nuclear RNA (snRNA) Promoters
What the sources say
- Partly supportedcites [134] Eckenfelder, 2012, The Cellular Processing Capacity Limits the Amounts of Chimeric U7 snRNA Available for Antisense Delivery, Mol. Ther. Nucleic Acids sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [135] Salva, 2007, Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle, Mol. Ther. source
- Disputedcites [136] LaVail, 2000, Ribozyme rescue of photoreceptor cells in P23H transgenic rats: Long-term survival and late-stage therapy, Proc. Natl. Acad. Sci. USA sourceExperimental — accuracy not yet measured
The Abstract (page unavailable) describes a different construct: rAAV vectors used a proximal bovine rod opsin promoter to express hairpin or hammerhead ribozymes in rat photoreceptors. Those ribozymes targeted mutant rhodopsin transcripts; the paper does not describe MHCK7-driven, HDV/hammerhead-flanked CRISPR gRNAs in myotubes. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [137] Xu, L., Zhao, L., Gao, Y., Xu, J., and Han, R. (2017). Empower multiplex cell and tissue-specific CRISPR-mediated gene manipulation with self-cleaving ribozymes and tRNA. Nucleic Acids Res., 45. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However, if left active in cells, functional rAAV-CRISPR/Cas9 systems do increase the number of off-target integration events into the genome [218].”
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 4.3. rAAV-Vectors Expressing CRISPR/Cas
What the sources say
- Disputedcites [218] Hanlon, K.S., Kleinstiver, B.P., Garcia, S.P., Zaborowski, M.P., Volak, A., Spirig, S.E., Muller, A., Sousa, A.A., Tsai, S.Q., and Bengtsson, N.E. (2019). High levels of AAV vector integration into CRISPR-induced DNA breaks. Nat. Commun., 10. sourceExperimental — accuracy not yet measured
The Results (Genome-wide AAV mapping from mouse brain) report no increase in the overall number of integration sites when Cas9 and gRNA were both present, and say integration at predicted off-target cut sites was below detection. The Discussion likewise reports no significant increase in overall AAV integration with Cas9; the increase was at CRISPR target sites, not off-target sites. The paper raises sustained nuclease activity as a potential concern but does not report the claimed off-target increase. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Because of the relatively large size of 4277 bp of dCas9-VPR cDNA, the authors used a dual rAAV system to express the dCas9-VPR and gRNA expression cassettes [223,224].”
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 4.3. rAAV-Vectors Expressing CRISPR/Cas
What the sources say
- Disputedcites [223] Kocak, 2013, RNA-guided gene activation by CRISPR-Cas9-based transcription factors, Nat. Methods sourceExperimental — accuracy not yet measured
The paper’s Online Methods (Plasmids; Cell culture and transfection, page unavailable) describe a dCas9-VP64 construct and transfection of plasmids encoding dCas9-VP64 and gRNAs, not a dual rAAV system expressing dCas9-VPR. Our copy does not give a 4277-bp dCas9-VPR cDNA size or attribute the delivery method to that size. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Disputedcites [224] Konermann, 2015, Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex, Nature sourceExperimental — accuracy not yet measured
The Extended Data Figure 7 caption describes three lentiviral vectors expressing sgRNA, dCas9-VP64, and MS2-p65-HSF1, not a dual rAAV system expressing dCas9-VPR and gRNA. The genome-scale gene activation screen section likewise identifies the delivery system as lentiviral. These passages do not give a 4277-bp dCas9-VPR cDNA size. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The hypoxia-induced Müller glial specific promoter showed no luciferase expression in HEK293, C6, HT22, and ARPE19 cells [97].”
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 5.1. In Vitro Immortalized Epithelial Cell Lines for Transgene and Bioactivity Assays
What the sources say
- Disputedcites [97] Prentice, 2011, Hypoxia-regulated retinal glial cell-specific promoter for potential gene therapy in disease, Investig. Ophthalmol. Vis. Sci. sourceExperimental — accuracy not yet measured
The Figure 4 caption says the regulated promoter had basal or minimal expression in HEK, C6, HT22, and ARPE-19 cells, not no expression. The Hypoxic Induction and Cell Specificity section reports no hypoxic induction in those lines; that does not establish an absence of luciferase expression. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The ubiquitous UbC promoter showed no toxicity to the mouse RPE [324].”
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 5.6.4. Cis-Regulatory Toxicity of rAAV Vectors In Vivo?
What the sources say
- Disputedcites [324] Xiong, 2019, AAV cis-regulatory sequences are correlated with ocular toxicity, Proc. Natl. Acad. Sci. USA sourceExperimental — accuracy not yet measured
The Results section on RPE toxicity says the broadly active UbiC promoter induced strong RPE toxicity, the opposite of the claim. The study used subretinal AAV injections in mice, as described in the Results section on photoreceptor toxicity. (LLM, conf=0.95)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
203 more claims · 84 with their cited sources checked
Create a free account to see all 366 claims and to verify the 4 references still open.
- It may state two separate claims as one. 107
- Probably not a substantial claim. 78
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The immune reactions include induction of neutralizing antibodies that reduce the number of capsids reaching the target cells, innate immune pathways silencing the gene cassette within the host cell, and cell-mediated T-cell immune responses against foreign protein expression.”
From Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses (2022) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unlike adenoviruses, AAVs generate relatively mild innate and adaptive immune responses, which allow for stable long-term transgene expression.”
From Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses (2022) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Since then, AAV-mediated gene delivery into the retina has been used in several proof-of-concept studies to target photoreceptors or the RPE in mice and larger models (such as dogs) [63,64,65].”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [63]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 2. Ocular rAAV Vector-Based Therapies in Clinical Trials
“a promoter shortened to 750 bp (NA65p)”
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 7.1. A Meta-Analysis on Pro-Viral Plasmids and Production Platforms for Ocular rAAV Therapies in Clinical Trials
“| NA65p | 1383 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > Additional information
“Lentiviral products, cell therapy products, antibodies, and antisense oligonucleotide (AONs) products were removed from Figure 3 and Table 1 to include only rAAV-based therapies.”
§ Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays > 7.1. A Meta-Analysis on Pro-Viral Plasmids and Production Platforms for Ocular rAAV Therapies in Clinical Trials
“| Usher | | UshStat | EIAV | CMV | | WPRE | MYO7A | SIN-LTR | HEK293 | | Usher | | QR-421a | | | | AON-USH2A | | | Synthetic |”
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Sun, 2010, Gene therapy with a promoter targeting both rods and cones rescues retinal degeneration caused by AIPL1 mutations, Gene Ther., 17, 117, 10.1038/gt.2009.104”
Cited work 10.1038/gt.2009.104 · retracted 2024-11-15 · notice 10.1038/s41434-024-00505-6 · this paper published 2020-06-12
Citations
Cites
1 retracted
Items 201–309 of 309
Watanabe, S., Sanuki, R., Ueno, S., Koyasu, T., Hasegawa, T., & Furukawa, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054146 · Cited by 59 · cited 1×
“Crx2kb 2000 Cone and rod PRCs [122] ProA1 2000 cone PRCs [50] ProA4 2000 cone PRCs [50] ProC1 731 Cone and rod PRCs [50]”
BackgroundPatrício, M. I., Barnard, A. R., Orlans, H. O., McClements, M. E., & MacLaren, R. E. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2016.12.006 · Cited by 59 · cited 1×
“pA vectors with or without WPRE were applied to human retinal explants or injected in mouse eyes [138].”
MethodOcular gene transfer with self-complementary AAV vectors
Yokoi, K., Kachi, S., Zhang, H. S., Gregory, P. D., Spratt, S. K., Samulski, R. J., & Campochiaro, P. A. (2007) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-1306 · Cited by 58 · cited 1×
“When compared to ssDNA, lowered rAAV doses of scAAV gene therapy vector can be used to reach similar transgene expression levels in the retina in vivo [101,152,256,257].”
BackgroundSpecific tools for targeting and expression in Müller glial cells
Pellissier, L. P., Hoek, R. M., Vos, R. M., Aartsen, W. M., Klimczak, R. R., Hoyng, S. A., Flannery, J. G., & Wijnholds, J. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.9 · Cited by 58 · cited 7×
“(4) rAAV DNA carrier systems spread well within tissues to target large retinal patches [24].”
BackgroundInfluentialSelf-citationJo, D. H., Koo, T., Cho, C. S., Kim, J. H., Kim, J.-S., & Kim, J. H. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.10.009 · Cited by 57 · cited 1×
“Their follow-up paper showed that 14-months post-injection, the CjCas9 is still active but does not affect the retinal function indicating that the therapy might be safe [222].”
BackgroundStrobel, B., Spöring, M., Klein, H., Blazevic, D., Rust, W., Sayols, S., Hartig, J. S., & Kreuz, S. (2020) · Nature Communications · doi:10.1038/s41467-020-14491-x · Cited by 57 · cited 2×
“Riboswitches ~100 ligand-sensing aptamer, a communication module (linker), and an effector domain (ribozyme) [173,178,179]”
BackgroundBrydon, E. M., Bronstein, R., Buskin, A., Lako, M., Pierce, E. A., & Fernandez-Godino, R. (2019) · doi:10.1101/729160 · Cited by 56
Foster, L. C., Wiesel, P., Huggins, G. S., Pañares, R., Chin, M. T., Pellacani, A., & Perrella, M. A. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.2.368 · Cited by 54 · cited 1×
“RLBP1 2789 Müller glial cells [24,89] Short RLBP1 581 Müller glial cells [101] Murine CD44 1775 Müller glial cells [24,95] Murine shCD44 363 Müller glial cells [24,103] ProB2 592 Müller glial cells [50]”
BackgroundCharbel Issa, P., De Silva, S. R., Lipinski, D. M., Singh, M. S., Mouravlev, A., You, Q., Barnard, A. R., Hankins, M. W., During, M. J., & MacLaren, R. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060361 · Cited by 53 · cited 1×
“The potency to infect the degenerate photoreceptors by subretinal injection of Abca4KO mice compared to wild-type mice was lower for four different rAAVs (rAAV2, rAAV5, rAAV2rec2, rAAV2rec3) while the potency to infect INL cells was increased in Pde6brd1/rd1 mice at least for rAAV5, rAAV2/Rec2 [309].”
BackgroundBrydon, E. M., Bronstein, R., Buskin, A., Lako, M., Pierce, E. A., & Fernandez-Godino, R. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.10.014 · Cited by 53
Mechanisms of AAV transduction in glaucoma‐associated human trabecular meshwork cells
Borrás, T., Xue, W., Choi, V. W., Bartlett, J. S., Li, G., Samulski, R. J., & Chisolm, S. S. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.886 · Cited by 51 · cited 1×
“Still, the surrogate cell line might also be interesting for studying the off-target effects of rAAV vectors injected intravitreally [262,263].”
BackgroundOkada, T., Uchibori, R., Iwata-Okada, M., Takahashi, M., Nomoto, T., Nonaka-Sarukawa, M., Ito, T., Liu, Y., Mizukami, H., Kume, A., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.010 · Cited by 51 · cited 1×
“However, chromatin immunoprecipitation did pull down rAAV concatemer vectors after treatment with histone deacetylase inhibitor FR901228 of rAAV infected cells suggesting that rAAV might interact with histone-associated chromatin [240].”
BackgroundAAV8-antiVEGFfab Ocular Gene Transfer for Neovascular Age-Related Macular Degeneration
Liu, Y., Fortmann, S. D., Shen, J., Wielechowski, E., Tretiakova, A., Yoo, S., Kozarsky, K., Wang, J., Wilson, J. M., & Campochiaro, P. A. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.12.002 · Cited by 51 · cited 1×
“Nonmembrane associated splice variant of VEGFR1 encoded by the FLT1 gene; Adverum Biotechnologies; Sanofi Genzyme) [41,205,206], (2) endostatin (cleavage product of collagen XVIII) / angiostatin (cleavage product of fibrinogen; Oxford Biomedica) [207], (3) the complement factor I (CFI, a C3b/C4b inactivator in the com…”
BackgroundReid, C. A., Ertel, K. J., & Lipinski, D. M. (2017) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22281 · Cited by 51
Cone-specific expression using a human red opsin promoter in recombinant AAV
Li, Q., Timmers, A. M., Guy, J. R., Pang, J., & Hauswirth, W. W. (2007) · Vision Research · doi:10.1016/j.visres.2007.07.026 · Cited by 50 · cited 1×
“IRBPe/GNAT2 500 Cone PRCs [115] Mouse CAR / ARR3 500 Cone PRCs, some rods, and RPE [115] Human CAR / ARR3 405-500 Cone PRCs, some rods, and RPE cells [115,116] CAR / ARR3 215 Cone PRC [117] Human red opsin 2,100 Human red cone opsin [118]”
BackgroundCrémisi, C., Pignatti, P. F., & Yaniv, M. (1976) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(76)90845-7 · Cited by 50 · cited 1×
“Chromatin-modifying proteins have been extensively studied but are viewed as less relevant for rAAV vectors because rAAV vector DNA, resides mainly in a concatemeric-episomal conformation in the nucleus, therefore potentially less regulated by epigenetics [23,239].”
BackgroundTargeted ablation of Crb2 in photoreceptor cells induces retinitis pigmentosa
Alves, C. H., Pellissier, L. P., Vos, R. M., Garrido, M. G., Sothilingam, V., Seide, C., Beck, S. C., Klooster, J., Furukawa, T., Flannery, J. G., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu048 · Cited by 50
Self-citationFrançois, A., Bouzelha, M., Lecomte, E., Broucque, F., Penaud-Budloo, M., Adjali, O., Moullier, P., Blouin, V., & Ayuso, E. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.07.004 · Cited by 50 · cited 1×
“The HeLaRC32 cells allow rAAV replication if the rAAV gene cassette can enter the nucleus [259].”
BackgroundXu, D., Wang, X., Jia, Y., Wang, T., Tian, Z., Feng, X., & Zhang, Y. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13504 · Cited by 50
CRB2 acts as a modifying factor of CRB1-related retinal dystrophies in mice
Pellissier, L. P., Lundvig, D. M. S., Tanimoto, N., Klooster, J., Vos, R. M., Richard, F., Sothilingam, V., Garcia Garrido, M., Le Bivic, A., Seeliger, M. W., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu089 · Cited by 49
Self-citationRlbp1 Promoter Drives Robust Müller Glial GFP Expression in Transgenic Mice
Va´zquez-Chona, F. R., Clark, A. M., & Levine, E. M. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3189 · Cited by 48 · cited 1×
“RLBP1 2789 Müller glial cells [24,89] Short RLBP1 581 Müller glial cells [101] Murine CD44 1775 Müller glial cells [24,95] Murine shCD44 363 Müller glial cells [24,103] ProB2 592 Müller glial cells [50]”
BackgroundPreferential association of newly synthesized histones with replicating SV40 DNA
Crémisi, C., Chestier, A., & Yaniv, M. (1977) · Cell · doi:10.1016/0092-8674(77)90159-3 · Cited by 48 · cited 1×
“Moreover, viral DNA in minichromosomal confirmation has an identical density to chromosomal DNA indicative that chromatin-modifying factors might play a role for rAAV vectors [241].”
BackgroundKoilkonda, R. D. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.135 · Cited by 48 · cited 1×
“When compared to ssDNA, lowered rAAV doses of scAAV gene therapy vector can be used to reach similar transgene expression levels in the retina in vivo [101,152,256,257].”
BackgroundDuong, T. T., Vasireddy, V., Ramachandran, P., Herrera, P. S., Leo, L., Merkel, C., Bennett, J., & Mills, J. A. (2018) · Stem Cell Research · doi:10.1016/j.scr.2018.01.009 · Cited by 48 · cited 1×
“The patient hiPSC-derived RPE can be efficiently used for testing the AAV-CHM vector for rescuing prenylation, phagocytosis, and protein trafficking [280].”
MethodOng, S. T., Li, F., Du, J., Tan, Y. W., & Wang, S. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1404 · Cited by 47
Young, J. E., Vogt, T., Gross, K. W., & Khani, S. C. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.03-0197 · Cited by 47
Gao, Z., Harwig, A., Berkhout, B., & Herrera-Carrillo, E. (2017) · Transcription · doi:10.1080/21541264.2017.1322170 · Cited by 47 · cited 1×
“However, the relatively large size, the requirement that the transcript starts with a G or A, the sometimes too active transcription, and the sensitivity to specific cellular profiles make the human U6 promoter a less versatile promoter [88,131,132].”
BackgroundSurace, E. M., Auricchio, A., Reich, S. J., Rex, T., Glover, E., Pineles, S., Tang, W., O'Connor, E., Lyubarsky, A., Savchenko, A., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.14.7957-7963.2003 · Cited by 46 · cited 4×
“However, the access to and quality of the donor human fetal material limits the application for many researchers [62,299,300].”
BackgroundInfluentialWang, Z., Lisowski, L., Finegold, M. J., Nakai, H., Kay, M. A., & Grompe, M. (2012) · Molecular Therapy · doi:10.1038/mt.2012.157 · Cited by 44 · cited 1×
“Further, many rAAV gene cassette integrations caused deletions in the genome [251].”
BackgroundOsborne, A., Wang, A. X. Z., Tassoni, A., Widdowson, P. S., & Martin, K. R. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.069 · Cited by 43
Simpson, E. M., Korecki, A. J., Fornés, O., McGill, T. J., Vargas, J. L. C., Agostinone, J., Farkas, R. A., Hickmott, J. W., Lam, S. L., Mathelier, A., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.118 · Cited by 43 · cited 1×
“+++ (stronger than smCBA) [127] RPE Size (bp) Origin, Cell Expression, Strength References”
BackgroundRational design of a compact CRISPR-Cas9 activator for AAV-mediated delivery
Vora, S., Cheng, J., Xiao, R., VanDusen, N. J., Quintino, L., Pu, W. T., Vandenberghe, L. H., Chavez, A., & Church, G. (2018) · doi:10.1101/298620 · Cited by 42 · cited 3×
“A modified rAAV-vector version with a full-length CMV promoter and the bGHpolyA efficiently upregulated a gene (Actc1, Neurog2, or Hbb) upon infection of N2A neuron derived cells by 50-150x in vitro [167].”
BackgroundQuinn, P. M. J., Mulder, A. A., Alves, C. H., Desrosiers, M., de Vries, S. I., Klooster, J., Dalkara, D., Koster, A. J., Jost, C. R., & Wijnholds, J. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy337 · Cited by 42
Self-citation(2011) · PubMed Central · Cited by 41
Adeno-associated virus of a single-polarity DNA genome is capable of transduction in vivo
Zhou, X., Zeng, X., Fan, Z., Li, C., McCown, T., Samulski, R. J., & Xiao, X. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300397 · Cited by 41
Aartsen, W. M., van Cleef, K. W. R., Pellissier, L. P., Hoek, R. M., Vos, R. M., Blits, B., Ehlert, E. M. E., Balaggan, K. S., Ali, R. R., Verhaagen, J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012387 · Cited by 41 · cited 1×
“CHX10 164 Retinal progenitor cells [98] GFAP 2600 Müller glial cells, [99,100] GFAP 2200 Müller glial cells (Novartis) [101] GfaABC1D 686 Müller glial cells [96,97]”
BackgroundSelf-citationWang, L., Xiao, R., Andres-Mateos, E., & Vandenberghe, L. H. (2017) · PLOS ONE · doi:10.1371/journal.pone.0182473 · Cited by 41 · cited 1×
“Still, the surrogate cell line might also be interesting for studying the off-target effects of rAAV vectors injected intravitreally [262,263].”
BackgroundGlushakova, L. G., Timmers, A. M., Pang, J., Teusner, J. T., & Hauswirth, W. W. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-1670 · Cited by 39 · cited 1×
“Human blue opsin HB570 570 S-cone and subset of M-cones PRCs [111] Human blue opsin HB569 569 blue cone opsin PRCs [106,112] PR0.”
BackgroundGenome-wide RNAi screening identifies host restriction factors critical for in vivo AAV transduction
Mano, M., Ippodrino, R., Zentilin, L., Zacchigna, S., & Giacca, M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1503607112 · Cited by 39 · cited 1×
“Besides, the knockdown of chromatin assembly factor 1 increased rAAV transduction in HeLa cells [242].”
BackgroundAlves, C. H., Bossers, K., Vos, R. M., Essing, A. H. W., Swagemakers, S. M. A., van der Spek, P. J., Verhaagen, J., & Wijnholds, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082532 · Cited by 39
Self-citationDNA Minicircle Technology Improves Purity of Adeno-associated Viral Vector Preparations
Schnödt, M., Schmeer, M., Kracher, B., Krüsemann, C., Espinosa, L. E., Grünert, A., Fuchsluger, T., Rischmüller, A., Schleef, M., & Büning, H. (2016) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2016.60 · Cited by 39 · cited 1×
“Moreover, the use of minicircle plasmids during rAAV production allowed for high transduction titers of rAAV vectors on HeLa cells [229].”
BackgroundStroma-dependent apoptosis in clonal hematopoietic precursors correlates with expression of PYCARD
Mhyre, A. J., Marcondes, A. M., Spaulding, E. Y., et al. (2008) · Blood · doi:10.1182/blood-2008-04-152686 · Cited by 37 · cited 1×
“PolII miR-155 ~500 Block-iT PolII miR vector system based on miR-155 expressing artificial miRNAs engineered to a target sequence resulting in target cleavage [162]”
BackgroundStructure and regulation of the sheep metallothionein-Ia gene
PETERSON, M. G., & MERCER, J. F. B. (1986) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1986.tb10077.x · Cited by 37 · cited 1×
“MT-1 13200 Zinc, cadmium or copper-inducible sheep metallothionine-Ia promoter [174]”
BackgroundSynthetic Intron Improves Transduction Efficiency of Trans -Splicing Adeno-Associated Viral Vectors
Lai, Y., Yue, Y., Liu, M., & Duan, D. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.1036 · Cited by 37 · cited 1×
“Inclusion of natively occurring or synthetic introns can strongly boost protein expression, especially for vectors with low efficiency of gene splitting sites [142].”
BackgroundHypoxia-regulated retinal glial cell-specific promoter for potential gene therapy in disease
Prentice, H. M., Biswal, M. R., Dorey, C. K., & Blanks, J. C. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6835 · Cited by 35 · cited 3×
“HRSE from metallothionein II promoter (90 bps) [97,102]”
BackgroundA novel dicistronic AAV vector using a short IRES segment derived from hepatitis C virus genome
Urabe, M., Hasumi, Y., Ogasawara, Y., Matsushita, T., Kamoshita, N., Nomoto, A., Colosi, P., Kurtzman, G. J., Tobita, K., & Ozawa, K. (1997) · Gene · doi:10.1016/s0378-1119(97)00412-5 · Cited by 35
AAV-mediated RLBP1 gene therapy improves the rate of dark adaptation in Rlbp1 knockout mice
Choi, V. W., Bigelow, C. E., McGee, T. L., Gujar, A. N., Li, H., Hanks, S. M., Vrouvlianis, J., Maker, M., Leehy, B., Zhang, Y., et al. (2015) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.22 · Cited by 35 · cited 2×
“When compared to ssDNA, lowered rAAV doses of scAAV gene therapy vector can be used to reach similar transgene expression levels in the retina in vivo [101,152,256,257].”
BackgroundNew Insights in the Optic Radiations Connectivity in the Human Brain.
Arrigo, A., Calamuneri, A., Mormina, E., Gaeta, M., Quartarone, A., Marino, S., Anastasi, G., & Aragona, P. (2016) · PubMed · doi:10.1167/iovs.15-18082 · Cited by 35
Vector characterization methods for quality control testing of recombinant adeno-associated viruses
Wright, J. F., & Zelenaia, O. (2011) · Methods in Molecular Biology · doi:10.1007/978-1-61779-095-9_11 · Cited by 34 · cited 1×
“Quality control includes testing the rAAV production on safety (sterility, viral contaminants, mycoplasma, endotoxins, bacterial and fungistatic activity), appearance, pH, osmolarity, potency (viral genome titer, infectivity, expression), purity, and vector genome identity [258].”
BackgroundA novel retinal ganglion cell promoter for utility in AAV vectors
Hanlon, K. S., Chadderton, N., Palfi, A., Blanco Fernandez, A., Humphries, P., Kenna, P. F., Millington-Ward, S., & Farrar, G. J. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00521 · Cited by 34
Engineered Promoters for Potent Transient Overexpression
Even, D. Y., Kedmi, A., Basch-Barzilay, S., Ideses, D., Tikotzki, R., Shir-Shapira, H., Shefi, O., & Juven‐Gershon, T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148918 · Cited by 33 · cited 2×
“core CMV 30 Not active without enhancers [48]”
BackgroundDuong, T. T., Lim, J., Vasireddy, V., Papp, T., Nguyen, H., Leo, L., Pan, J., Zhou, S., Chen, H. I., Bennett, J., et al. (2019) · Stem Cells International · doi:10.1155/2019/7281912 · Cited by 33 · cited 1×
“rAAV DNA carrier systems have been successfully used because they have a plethora of advantages: (1) They express the transgene within days or weeks and can reach full expression levels after 4–6 weeks in vivo [20,21].”
BackgroundAdeno-associated virus inverted terminal repeats stimulate gene editing
Hirsch, M. L. (2015) · Gene Therapy · doi:10.1038/gt.2014.109 · Cited by 32 · cited 6×
“This basic rAAV gene delivery vector can consist of two inverted terminal repeats (ITRs) of the AAV serotype 2 (ITR2), a promoter, a wild-type copy of the cDNA of the gene-of-interest, as well as other enhancers or transcript stabilizing elements, an intron, and a polyadenylation sequence (Figure 2B).”
BackgroundInfluentialQuinn, P. M. J., Alves, C. H., Klooster, J., & Wijnholds, J. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy194 · Cited by 32
Self-citationHager, S., Frame, F. M., Collins, A. T., Burns, J. E., & Maitland, N. J. (2008) · Human Gene Therapy · doi:10.1089/hum.2007.165 · Cited by 30 · cited 1×
“For example, whereas polyA’s increase transcript stability/expression, certain polyadenylation sequences can also reduce viral titers during rAAV particle production [168].”
BackgroundLeVaillant, C. J., Sharma, A., Muhling, J., Wheeler, L. P. G., Cozens, G. S., Hellström, M., Rodger, J., & Harvey, A. R. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.78 · Cited by 30
Cehajic-Kapetanovic, J., Milosavljevic, N., Bedford, R. A., Lucas, R. J., & Bishop, P. N. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.12.002 · Cited by 30 · cited 1×
“Enzymatic digestion (proteasome inhibitors) of the ILM or ILM/outer limiting membrane (OLM) or disruptions of the ILM/OLM by the disease can alter rAAV infection and allow rAAV infection deeper into the retina [99,294,304,305].”
BackgroundPost-Vitrectomy Endophthalmitis in Victoria, Australia
Chandra, A., Smith, J. D., Wang, B. Z., Kurniawan, E. D., Kam, J., Sandhu, S. S., & Allen, P. J. (2016) · Asia-Pacific Journal of Ophthalmology · doi:10.22608/apo.2016126 · Cited by 28 · cited 1×
“, RhoA-Rho kinases and prostaglandin EP4 agonists) [203].”
(1999) · Europe PMC (PubMed Central) · Cited by 27
Fagoe, N. D., Eggers, R., Verhaagen, J., & Mason, M. R. J. (2014) · Gene Therapy · doi:10.1038/gt.2013.71 · Cited by 27 · cited 1×
“Placing two promoters in opposing directions next to each other also allows efficient bicistronic gene expression from one gene cassette [75].”
BackgroundTransduction of the inner mouse retina using AAVrh8 and AAVrh10 via intravitreal injection
Giove, T. J., Sena-Esteves, M., & Eldred, W. D. (2010) · Experimental Eye Research · doi:10.1016/j.exer.2010.08.011 · Cited by 27 · cited 1×
“Intravitreal injection of rAAVrh-10 shifted infection from mainly INL cells towards photoreceptor and RPE cells in Rs1KO and RhoKO mice (XLRS and RP models, respectively) compared to wild-type mice [310,311].”
ResultGilham, D. E., Lie‐A‐Ling, M., Taylor, N. N., & Hawkins, R. E. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1421 · Cited by 27 · cited 1×
“(TATA box, Inr, MTE and DPE) [48] EF1-α 2500 Ubiquitous, ++ [51,70] PGK 426 Ubiquitous, ++ [53] UbC 403 Ubiquitous, ++ [70]”
AAV2-Mediated Transduction of the Mouse Retina After Optic Nerve Injury
Nickells, R. W., Schmitt, H. M., Maes, M. E., & Schlamp, C. L. (2017) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22634 · Cited by 27
McFarland, T. J., Zhang, Y., Atchaneeyaskul, L.-O., Francis, P., Stout, J. T., & Appukuttan, B. (2006) · Plasmid · doi:10.1016/j.plasmid.2005.11.005 · Cited by 26
Lu, J., Williams, J. A., Luke, J., Zhang, F., Chu, K., & Kay, M. A. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.140 · Cited by 26
Satkunanathan, S., Wheeler, J., Thorpe, R., & Zhao, Y. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.041 · Cited by 24
Petit, L., Ma, S., Cheng, S.-Y., Gao, G., & Punzo, C. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.020 · Cited by 24
Zhou, Q., Tian, W., Liu, C., Lian, Z., Dong, X., & Wu, X. (2017) · Scientific Reports · doi:10.1038/s41598-017-04054-4 · Cited by 23 · cited 1×
“A systematical study into ITR mutations (deleting B-B and C-C’ regions) indicated a reduced yield (4-8x fold) but a 4-fold increased transgene expression in HEK293 cells 72 hours post-infection [237].”
BackgroundPatrício, M. I., Barnard, A. R., Cox, C. I., Blue, C. E., & MacLaren, R. E. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.03.009 · Cited by 22 · cited 1×
“The rAAV-REP1 for the treatment of choroideremia is assessed on in vitro prenylation of RAB6A in HEK293 cells [261].”
Background(2008) · PubMed Central · Cited by 21
Pleticha, J., Heilmann, L. F., Evans, C. H., Asokan, A., Samulski, R. J., & Beutler, A. S. (2014) · Molecular Pain · doi:10.1186/1744-8069-10-54 · Cited by 21 · cited 2×
“very safe with a low number of serious adverse events (SAE) in clinical trials [26].”
BackgroundCRISPR Activation Enhances In Vitro Potency of AAV Vectors Driven by Tissue-Specific Promoters
McDougald, D. S., Duong, T. T., Palozola, K. C., Marsh, A., Papp, T. E., Mills, J. A., Zhou, S., & Bennett, J. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.03.004 · Cited by 21 · cited 1×
“The 661W cell line has been further modified to achieve improved transfection by overexpression of the universal adeno-associated virus receptor (AAVR) or more stably express key photoreceptor genes such as GRK1 and CAR by rAAV-VPR-dCas9 vector infection [269].”
BackgroundCone Specific Promoter for Use in Gene Therapy of Retinal Degenerative Diseases
Dyka, F. M., Boye, S. L., Ryals, R. C., Chiodo, V. A., Boye, S. L., & Hauswirth, W. W. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-3209-8_87 · Cited by 20 · cited 1×
“IRBPe/GNAT2 500 Cone PRCs [115] Mouse CAR/ARR3 500 Cone PRCs, some rods, and RPE [115] Human CAR/ARR3 405–500 Cone PRCs, some rods, and RPE cells [115,116] CAR/ARR3 215 Cone PRC [117] Human red opsin 2100 Human red cone opsin [118]”
BackgroundA small regulatory element from chromosome 19 enhances liver-specific gene expression
Li, C., Hirsch, M. L., Carter, P. J., Asokan, A., Zhou, X., Wu, Z., & Samulski, R. J. (2008) · Gene Therapy · doi:10.1038/gt.2008.134 · Cited by 20
Quiambao, A. B., Peachey, N. S., Mangini, N. J., Röhlich, P., Hollyfield, J. G., & Al‐Ubaidi, M. R. (1997) · Visual Neuroscience · doi:10.1017/s095252380001258x · Cited by 20
Mouse Mammary Tumor Virus Sequences Responsible for Activating Cellular Oncogenes
Grimm, S. L., & Nordeen, S. K. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9428-9435.1998 · Cited by 20 · cited 1×
“Active when glucocorticoids or progestins present [175,176]”
Song, C., Conlon, T. J., Deng, W.-T., Coleman, K. E., Zhu, P., Plummer, C., Mandapati, S., Van Hoosear, M., Green, K. B., Sonnentag, P., et al. (2018) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2018.168 · Cited by 20 · cited 2×
“Such adaptations in the AGTC-501 vector resulted in reduced frequency of alternative splicing and increased mRNA stability [43,110].”
BackgroundReversal of ageing- and injury-induced vision loss by Tet-dependent epigenetic reprogramming
Lu, Y., Krishnan, A., Brommer, B., Tian, X., Meer, M., Vera, D. L., Wang, C., Zeng, Q., Yu, D., Bonkowski, M. S., et al. (2019) · doi:10.1101/710210 · Cited by 20 · cited 1×
“The rAAV9-Oct4/Sox2/Klf4 expression vector rescued ganglion cell survival in an optic nerve crush mouse model [71].”
BackgroundParker, M., Bellec, J., McFarland, T. J., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.079 · Cited by 19
Pickrell, S. W., Zhu, X., Wang, X., & Craft, C. M. (2004) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.04-0663 · Cited by 19 · cited 4×
“Sci. 2020, 21, 4197 34 of 52 CB-SB shortened CBA promoter containing a CMV early enhancer element CMV cytomegalovirus early enhancer element and promoter EBV Epstein Barr Virus ERG Electroretinogram (retinal function) GCL Ganglion cell layer GMP good manufacturing practice hCAR human cone arrestin hCNGA3 Human (cone P…”
BackgroundInfluentialChanda, D., Hensel, J., Higgs, J., Grover, R., Kaza, N., & Ponnazhagan, S. (2017) · Genes · doi:10.3390/genes8090232 · Cited by 19 · cited 1×
“Recent studies indicated that the reduction of CpG islands in rAAV vectors increased transgene expression and reduced TLR9-mediated innate immune detection [46,47].”
BackgroundAl-Allaf, F. A., Abduljaleel, Z., Athar, M., Taher, M. M., Khan, W., Mehmet, H., Colakogullari, M., Apostolidou, S., Bigger, B., Waddington, S., et al. (2019) · Non-coding RNA Research · doi:10.1016/j.ncrna.2018.11.005 · Cited by 18
CRB2 Loss in Rod Photoreceptors Is Associated with Progressive Loss of Retinal Contrast Sensitivity
Alves, C. H., Boon, N., Mulder, A. A., Koster, A. J., Jost, C. R., & Wijnholds, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174069 · Cited by 18
Self-citationPerspectives on Best Practices for Gene Therapy Programs
Cheever, T. R., Berkley, D., Braun, S., Brown, R. H., Byrne, B. J., Chamberlain, J. S., Cwik, V. A., Duan, D., Federoff, H. J., High, K. A., et al. (2015) · Human Gene Therapy · doi:10.1089/hum.2014.147 · Cited by 17
Eckenfelder, A., Tordo, J., Babbs, A., Davies, K. E., Goyenvalle, A., & Danos, O. (2012) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2012.24 · Cited by 17 · cited 1×
“RNA polymerase III promoters also have been re-engineered with CMV enhancers [133] or tissue-specific enhancers (heart, muscle) for siRNA expression [134].”
MethodSong, H., Bush, R. A., Zeng, Y., Qian, H., Wu, Z., & Sieving, P. A. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.006 · Cited by 17 · cited 1×
“Applying a low trans-ocular electric current also allowed efficient transduction of RPE and photoreceptors by rAAV8 upon intravitreal injection in adult mice [306].”
BackgroundRetina transduction by rAAV2 after intravitreal injection: Comparison between mouse and rat
Dias, M. S., Araujo, V. G., Vasconcelos, T., Li, Q., Hauswirth, W. W., Linden, R., & Petrs-Silva, H. (2019) · Gene Therapy · doi:10.1038/s41434-019-0100-9 · Cited by 17 · cited 5×
“Enzymatic digestion (proteasome inhibitors) of the ILM or ILM/outer limiting membrane (OLM) or disruptions of the ILM/OLM by the disease can alter rAAV infection and allow rAAV infection deeper into the retina [99,294,304,305].”
BackgroundInfluentialCorrection: AAV9 Targets Cone Photoreceptors in the Nonhuman Primate Retina
Vandenberghe, L. H., Bell, P., Maguire, A. M., Xiao, R., Hopkins, T. B., Grant, R., Bennett, J., & Wilson, J. M. (2013) · PLoS ONE · doi:10.1371/annotation/64b90996-4634-4c63-b737-634397b0b445 · Cited by 16
AAV Serotype Testing on Cultured Human Donor Retinal Explants
Buck, T. M., Pellissier, L. P., Vos, R. M., van Dijk, E. H. C., Boon, C. J. F., & Wijnholds, J. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7522-8_20 · Cited by 15
Self-citationRNA-Based Therapeutic Strategies for Inherited Retinal Dystrophies
Garanto, A. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-27378-1_12 · Cited by 14 · cited 1×
“In the latter case, to prevent inhibition of the newly introduced gene, codon-optimization of the transgene might prevent inactivation by the gene-editing or siRNA tools used [80].”
MethodAAVrh-10 transduces outer retinal cells in rodents and rabbits following intravitreal administration
Zeng, Y., Qian, H., Wu, Z., Marangoni, D., Sieving, P. A., & Bush, R. A. (2019) · Gene Therapy · doi:10.1038/s41434-019-0094-3 · Cited by 12 · cited 2×
“Intravitreal injection of rAAVrh-10 shifted infection from mainly INL cells towards photoreceptor and RPE cells in Rs1KO and RhoKO mice (XLRS and RP models, respectively) compared to wild-type mice [310,311].”
BackgroundResultBishop, B. M., Santin, A. D., Quirk, J. G., & Hermonat, P. L. (1996) · FEBS Letters · doi:10.1016/s0014-5793(96)01149-0 · Cited by 11
Douar, A. M., Bouquet, C., Pruneau, D., Chavas, J., Dalkara, D., Duebel, J., Benosman, R., Chenegros, G., Picaud, S., Sahel, J., et al. (2016) · Molecular Therapy · doi:10.1016/s1525-0016(16)33077-5 · Cited by 11
Surrogate gene therapy for muscular dystrophy
Davies, K. E., & Chamberlain, J. S. (2019) · Nature Medicine · doi:10.1038/s41591-019-0604-2 · Cited by 11 · cited 2×
“Nevertheless, the microdystrophin rescue in patients in clinical trials has been at least suboptimal and needs further optimization [185].”
BackgroundChallenges in Retinal Circuit Regeneration: Linking Neuronal Connectivity to Circuit Function
Osakada, F., & Takahashi, M. (2015) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b14-00771 · Cited by 10
Martinez-Lopez, A., Encinas, P., García-Valtanen, P., Gomez-Casado, E., Coll, J. M., & Estepa, A. (2013) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-012-4403-7 · Cited by 9 · cited 2×
“When the sequence was used twice (2x sNRP-1 polyA), then the potency was as efficient as a single SV40polyA sequence [165,166].”
BackgroundMethodXiong, W., & Cepko, C. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-17121-0_67 · Cited by 9 · cited 1×
“Moreover, rAAV8-CMV-GFP transduces photoreceptors and Müller glial cells at postnatal day six but only transduces photoreceptors at postnatal day 0 [301].”
BackgroundIchsan, A. M., Kato, I., Yoshida, T., Takasawa, K., Hayasaka, S., & Hiraga, K. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2004.12.072 · Cited by 8 · cited 1×
“Mouse RHO 1400 Rod PRCs [104] Human RHO (rhodopsin) 800 Rod PRCs [105] Human RHO 520 Rod- PRCs [24]”
BackgroundGene- and Cell-Based Treatment Strategies for the Eye
(2015) · Essentials in Ophthalmology · doi:10.1007/978-3-662-45188-5 · Cited by 8
Lipinski, D. M. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-27378-1_13 · Cited by 8 · cited 2×
“Riboswitches ~100 ligand-sensing aptamer, a communication module (linker), and an effector domain (ribozyme) [173,178,179]”
BackgroundKwon, H.-J., Qing, K., Ponnazhagan, S., Wang, X.-S., Markusic, D. M., Gupte, S., Boye, S. E., & Srivastava, A. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.018 · Cited by 6 · cited 1×
“When high copy numbers of a D sequence expression vector are present in HEK293 cells, then the interferon-λ-mediated activation of the major histocompatibility complex class II (MHC-II) is dampened, potentially by the binding of the ds-D-BP protein with the D-sequence instead of the X-box (RFX) regulator [235].”
BackgroundFluorescence-based evaluation of shRNA efficacy
Naughton, B. J., Han, D. D., & Gu, H. H. (2011) · Analytical Biochemistry · doi:10.1016/j.ab.2011.06.008 · Cited by 5 · cited 2×
“The construct allows fast testing of the efficiency of shRNAs [177].”
BackgroundMcAlister, V. J., & Owens, R. A. (2010) · Virology Journal · doi:10.1186/1743-422x-7-218 · Cited by 5
Buchberger, A. M. S. (2016) · Figshare · Cited by 2
(2017) · Investigative Ophthalmology & Visual Science · Cited by 2
Self-citationRonzitti, G., Collaud, F., Bortolussi, G., Charles, S., Vidal, P., Sola, M. S., Muro, A. F., & Mingozzi, F. (2016) · Molecular Therapy · doi:10.1016/s1525-0016(16)32967-7 · Cited by 1
(2002) · Molecular Therapy · doi:10.1016/s1525-0016(16)43391-5 · Cited by 1
Development and efficacy assessment of AAV2/8-hG1.7p.coCNGA3, a CNGA3 gene therapy vector
Georgiadis, T., Matsuki, T., Hoke, J., et al. (2019) · Investigative Ophthalmology & Visual Science · Cited by 1
805. Fatality in Mice Due to Oversaturation of Cellular Micro/Short Hairpin RNA Pathways
Grimm, D., Streetz, K. L., Storm, T. A., Jopling, C. L., Lee, J. S., & Kay, M. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.08.1226
Research works printed but not linked: 5
- Fahim, A.T., Daiger, S.P., and Weleber, R.G. (2017, January 19). Nonsyndromic Retinitis Pigmentosa Overview, Available online: http://www.ncbi.nlm.nih.gov/pubmed/20301590.
- Kremer, J.M.J., Keunen, J.E.E., and van Wijk, H.A.R. (2018). Gene therapy using miniUSH2A genes improves visual function in a zebrafish ush2a knock-out model. Towards gene therapy for USH2A-associated retinitis pigmentosa. ~Fishing for answers~ [Doctoral Thesis], Radboud University Nijmegen.
- 2017, The pathway from genes to gene therapy in glaucoma: A review of possibilities for using genes as glaucoma drugs, Asia-Pacific J. Ophthalmol., 6, 80
- Ceiler, J., Afzal, S., Leuchs, B., Fronza, R., Lulay, C., Büning, H., Schmidt, M., and Gil-Farina, I. (2017, January 10). Wild-Type and Recombinant AAV Integration in Human Cardiomyocytes: Focus on Mitochondrial Genome. Proceedings of the AAV Vector Biology, Available online: https://www.researchgate.net/publication/316699961_Wild-Type_and_Recombinant_AAV_Integration_in_Human_Cardiomyocytes_Focus_on_Mitochondrial_Genome.
- Couto, 2016, Poster C0048 ARVO: Potency Assay for AAV Vector Encoding Retinal Pigment Epithelial 65 Protein, Investig. Ophthalmol. Vis. Sci., 57, 1
Cited by
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
“116 Another study reported that a fragment of the mouse methyl-CpG-binding protein-2 promoter enabled robust long-term expression speci fi cally in neurons.”
BackgroundGene therapy advances: A meta-analysis of AAV usage in clinical settings
Au, H. K. E., Isalan, M., & Mielcarek, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.809118 · Cited by 284
“Selecting the right capsid and promoter is the first step to improve targeted cell transduction and expression (2, 15).”
BackgroundAAV vector development, back to the future
Suárez-Amarán, L., Song, L., Tretiakova, A. P., Mikhail, S., & Samulski, R. J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.064 · Cited by 101
Nieuwenhuis, B., Laperrousaz, E., Tribble, J. R., Verhaagen, J., Fawcett, J. W., Martin, K. R. G., Williams, P. A., & Osborne, A. (2023) · Gene Therapy · doi:10.1038/s41434-022-00380-z · Cited by 88
Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses
Ghoraba, H. H., Akhavanrezayat, A., Karaca, I., Yavari, N., Lajevardi, S., Hwang, J., Regenold, J., Matsumiya, W., Pham, B., Zaidi, M., et al. (2022) · Clinical Ophthalmology · doi:10.2147/opth.s364200 · Cited by 76
“The immune reactions include induction of neutralizing antibodies that reduce the number of capsids reaching the target cells, innate immune pathways silencing the gene cassette within the host cell, and cell-mediated T-cell immune responses against foreign protein expression.(18)”
Background
Metadata
- Authors
- Buck, T., & Wijnholds, J.
- Affiliations
- Leiden University Medical Center (NL)
- Netherlands Institute for Neuroscience (NL)
- Corresponding author
- Wijnholds, Jan
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-06-12
- Volume
- 21
- Issue
- 12
- Pages
- 4197
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7352801
- OpenAlex
- W3035416273
- Cited by
- 92
- References
- 334
- Citations by year
- 2026: 10 · 2025: 17 · 2024: 17 · 2023: 15 · 2022: 16 · 2021: 15 · 2020: 2
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- KNAW Research Portal (The Royal Netherlands Academy of Arts and Sciences) (publishedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- KNAW research portal (Royal Academy of Art and Sciences (KNAW)) (submittedVersion, other-oa)
- Funders
- Foundation Fighting Blindness (TA-GT-0715-0665-LUMC)
- The Netherlands Organization for Health Research and Development (43200004)
- Million Dollar Bike Ride Grant Program (MDBR-19-131-CRB1, MDBR-20-112-CRB1)
- Dutch blindness funds (Uitzicht 2013-13)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus vectors, ocular gene therapy, inherited retinal disease, optic neuropathy, promoter, inverted terminal repeats, biological activity assay, retinal organoids, clinical trials
- MeSH terms
- Dependovirus, Clinical Trials as Topic, Genetic Vectors, Optic Nerve Diseases, Promoter Regions, Genetic, Genetic Therapy, Treatment Outcome, Polyadenylation, Capsid Proteins, Retinal Dystrophies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.